Table 2. Correlation between the clinicopathologic characteristics and MLH1/MSH2 expression.
| MLH1 | MSH2 | |||||
|---|---|---|---|---|---|---|
| Low | High | P value | Low | High | P value | |
| Age | ||||||
| < 60 years | 10 (34.5%) | 19 (65.5%) | 0.820a | 9 (31.0%) | 20 (69.0%) | 0.323a |
| ≥ 60 years | 24 (36.9%) | 41 (63.1%) | 14 (21.5%) | 51 (78.5%) | ||
| Gender | ||||||
| Male | 24 (38.1%) | 39 (61.9%) | 0.580a | 14 (22.2%) | 49 (77.8%) | 0.470a |
| Female | 10 (32.3%) | 21 (67.7%) | 9 (29.0%) | 22 (71.0%) | ||
| Tumor site | ||||||
| Head, neck | 16 (33.3%) | 32 (66.7%) | 0.505a | 14 (29.2%) | 34 (70.8%) | 0.306a |
| Body, tail | 18 (40.0%) | 27 (60.0%) | 9 (20.0%) | 36 (80.0%) | ||
| T stage | ||||||
| T1+T2 | 5 (25.0%) | 15 (75.0%) | 0.226a | 3 (15.0%) | 17 (85.0%) | 0.382a |
| T3+T4 | 29 (39.7%) | 44 (60.3%) | 20 (27.4%) | 53 (72.6%) | ||
| N stage | ||||||
| N0 (negative) | 14 (35.0%) | 26 (65.0%) | 0.786a | 7 (17.5%) | 33 (82.5%) | 0.160a |
| N1 (positive) | 20 (37.7%) | 33 (62.3%) | 16 (30.2%) | 37 (69.8%) | ||
| Metastasis | ||||||
| M0 (absent) | 33 (37.1%) | 56 (62.9%) | 1.000b | 21 (23.6%) | 68 (76.4%) | 0.255b |
| M1 (present) | 1 (25.0%) | 3 (75.0%) | 2 (50.0%) | 2 (50.0%) | ||
| Differentiation | ||||||
| G1 and G2 | 19 (31.1%) | 42 (68.9%) | 0.168a | 11 (18.0%) | 50 (82.0%) | 0.094a |
| G3 | 15 (45.5%) | 18 (54.5%) | 11 (33.3%) | 22 (66.7%) | ||
| Vascular invasion | ||||||
| No | 32 (39.5%) | 49 (60.5%) | 0.199a | 21 (25.9%) | 60 (74.1%) | 0.724a |
| Yes | 2 (16.7%) | 10 (83.3%) | 2 (16.7%) | 10 (83.3%) | ||
| Nervous invasion | ||||||
| No | 11 (39.3%) | 17 (60.7%) | 0.720a | 5 (17.9%) | 23 (82.1%) | 0.313a |
| Yes | 23 (35.4%) | 42 (64.6%) | 18 (27.7%) | 47 (72.3%) | ||
aChi-square test; bFisher's exact test